Rong-Chun Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Rong-Chun Li has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Cheng Liu
Fujian Provincial Key Laboratory of Fire Retardant Materials
1 shared publication - Chi Wai Cheung
Department of Anaesthesiology, School of Clinical Medicine, The University of Hong Kong, Hong Kong, China
1 shared publication - Defang Ding
Department of Imaging, Tongren Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
1 shared publication - Hongbing Xiang
Department of Anesthesiology and Pain Medicine, Hubei Key Laboratory of Geriatric Anesthesia and Perioperative Brain Health, Wuhan Clinical Research Center for Geriatric Anesthesia, Tongji Hospital, Tongji Medical College Huazhong University of Science and Technology Wuhan China
1 shared publication - Lei Hua
Department of Pain, Wuhan Fourth Hospital, Wuhan, China
1 shared publication - Mengjie Li
Department of Pain, Wuhan Fourth Hospital, Wuhan, China
1 shared publication
Latest Publications
- Open Access
- 7 March 2025
- Published by Universidad del Zulia in Investigación Clínica
- Vol. 66 (1) , 4-15
comPhillygenin reduced neuropathic pain by inhibiting the rats’ TLR4/MyD88/NF-κB pathway.
To elucidate the effects of phillygenin (PHI) and the potential mechanism on TLR4 and MyD88/NF-κB signalling in neuropathic pain in an-imal studies, chronic constriction injury (CCI) models were constructed for neuropathic pain induction using male Sprague-Dawley rats. PHI (20 mg/kg) was delivered through intragastric administration. Von Frey and Hargreaves tests were implemented to determine the 50% paw-withdrawal threshold (PWT) and paw-withdrawal latency (PWL). A nitric oxide (NO) assay was used for NO level detection, and an ELISA assay was employed to measure the expression of proinflammatory cytokines. Western blotting and RT-qPCR were conducted for protein and mRNA level detection. Treatment with PHI significantly enhanced 50% of PWT and PWL. PHI significantly decreased the levels of NO and reduced the levels of TNF-α, IL -1β, and IL -6. PHI also downregulated TLR4 and MyD88 expressions and inhibited the phosphorylation of NF-κB.PHI ameliorated in-flammatory status and alleviated neuropathic pain in CCI rats, targeting TLR4 and suppressing MyD88/NF-κB signalling.
- 7 March 2025
- Published by Universidad del Zulia in Investigación Clínica
- Vol. 66 (1) , 4-15
Open AccesscomPhillygenin reduced neuropathic pain by inhibiting the rats’ TLR4/MyD88/NF-κB pathway.
To elucidate the effects of phillygenin (PHI) and the potential mechanism on TLR4 and MyD88/NF-κB signalling in neuropathic pain in an-imal studies, chronic constriction injury (CCI) models were constructed for neuropathic pain induction using male Sprague-Dawley rats. PHI (20 mg/kg) was delivered through intragastric administration. Von Frey and Hargreaves tests were implemented to determine the 50% paw-withdrawal threshold (PWT) and paw-withdrawal latency (PWL). A nitric oxide (NO) assay was used for NO level detection, and an ELISA assay was employed to measure the expression of proinflammatory cytokines. Western blotting and RT-qPCR were conducted for protein and mRNA level detection. Treatment with PHI significantly enhanced 50% of PWT and PWL. PHI significantly decreased the levels of NO and reduced the levels of TNF-α, IL -1β, and IL -6. PHI also downregulated TLR4 and MyD88 expressions and inhibited the phosphorylation of NF-κB.PHI ameliorated in-flammatory status and alleviated neuropathic pain in CCI rats, targeting TLR4 and suppressing MyD88/NF-κB signalling.